{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-207423","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.719302+00:00","generated_at":"2026-06-11T21:40:08.162735+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Catalyst Q2 revenue $99.6M, GAAP EPS $0.33 (vs $0.20), raises FY2023 guide to $380M-$390M","bullets":["Q2 net product revenue $99.5M: FIRDAPSE $64.9M (+22% YoY); FYCOMPA $34.6M first-time contribution.","GAAP net income $37.8M, diluted EPS $0.33; Non-GAAP net income $60.4M, diluted EPS $0.53.","Raised FY2023 total revenue guidance to $380M-$390M.","Closed acquisition of North American vamorolone license for $75M in July; $15M Santhera equity investment and $10M Ruzurgi installment paid post-Q2.","Submitted sNDA for FIRDAPSE to increase maximum indicated dose to 100 mg/day."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-207423","json":"https://secwatch.observer/filing/0001193125-23-207423.json","markdown":"https://secwatch.observer/filing/0001193125-23-207423.md","text":"https://secwatch.observer/filing/0001193125-23-207423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523207423/0001193125-23-207423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523207423/d497533d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:40:08.162735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}